Acceleron Pharma (XLRN) Issues Interim Update on Two-Part Dalantercept Study as Ovarian Cancer Treatment
Tweet Send to a Friend
Acceleron Pharma Inc. (Nasdaq: XLRN) announced results from an interim report for a two-part clinical study sponsored by the Gynecology ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
